MINIject Shows Sustained 5-Year Efficacy in Glaucoma Treatment, iSTAR Medical Reports
• The STAR-GLOBAL trial demonstrated MINIject maintained a significant 38% reduction in intraocular pressure through five years, with 83% of patients achieving >20% IOP reduction from baseline.
• Over 5,000 patients worldwide have received the supraciliary MIGS device since its commercial launch, with data confirming a favorable long-term safety profile including corneal health.
• iSTAR Medical will continue independent development of MINIject following the conclusion of its partnership with AbbVie, with FDA submission targeted for 2028.
© Copyright 2025. All Rights Reserved by MedPath